CTLA4 and cancer: Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is another immune checkpoint that can impair T-cell function and Ipilimumab (an anti-CTLA-4 antibody) was the first immune checkpoint inhibitor approved for the treatment of cancer (374).